Premium
Protective effect of Diosmin on Lipopolysaccharide (LPS) ‐ induced PC12 cell death
Author(s) -
Benzeroual Kenza E,
Dholakiya Sanjay L
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.1004.8
Subject(s) - diosmin , western blot , viability assay , apoptosis , mtt assay , pharmacology , neuroprotection , lipopolysaccharide , programmed cell death , microbiology and biotechnology , cell , chemistry , medicine , biology , biochemistry , immunology , flavonoid , gene , antioxidant
Diosmin is a natural flavones glycoside therapeutically used to improve the symptoms of venous and lymphatic vessel insufficiency and also exhibits anti‐inflammatory properties. In the present study, LPS‐injured PC12 cells were used as an in vitro cell model of Alzheimer's disease (AD) to investigate the neuroprotective effects of diosmin. PC12 cells treated with LPS exhibited an increase in TNF‐alpha, and underwent apoptotic death as determined by western blot and agarose gel electrophoresis assay. The MTT assay results showed that pretreatment with diosmin produced a dose‐dependent increase in cell viability that was maximal at 5 μM of diosmin. Furthermore, western blot analysis showed a dose‐dependent decrease in the expression of TNF‐alpha when PC12 cells were pretreated with diosmin prior to treatment with LPS for 48 hours. Western blot and Caspase‐3 colorimetric assay revealed that diosmin exerts its anti‐apoptotic effects by decreasing the expression of pro‐apoptotic protein Bad, increasing the expression of antiapoptotic protein Bcl2, and decreasing caspase‐3 levels. The present study suggests that diosmin could be used as a neuroprotective agent to slow the progression of neurodegenerative diseases, including AD. Research suported by LIU‐College of Pharmacy